Pharma channel feed – Endpoints News

Pharma channel feed

Still hunting a blockbuster, Merck KGaA scores a win in the FDA approval column — more than 13 years in the making

7 years ago

BIO tells SEC: do away with quarterly reports for small biotechs

7 years ago

Takeda takes a cautious step into neurological gene therapy, inking preclinical deal with StrideBio

7 years ago

Bluebird's one-shot gene therapy for beta thalassemia officially secures EMA backing — approval expected in the second quarter

7 years ago

Top 20 cancer drug deals: AstraZeneca just changed the global landscape for dealmaking in oncology

7 years ago

Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up

7 years ago

Gottlieb seeks new comparative approval standard for opioids

7 years ago

Months after Imfinzi combo flops, AstraZeneca wins NICE endorsement as lung cancer monotherapy

7 years ago

We destroyed nearly 8,000 packs of expired Orkambi stock last year, Vertex tells UK MPs

7 years ago

FDA’s Oncology Center of Excellence touts 2018 accomplishments

7 years ago

AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales

7 years ago

Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune disease, cancer

7 years ago

Blockbuster to be? Novartis snags a major win as FDA OKs a top PhIII drug -- will a pricing controversy follow?

7 years ago

The top 10 Alzheimer's deals tell us a lot about a big change of direction for a disaster-prone field

7 years ago

FTC demands more info from Bristol-Myers, Celgene on psoriasis drugs, signaling a potential hitch for $74B deal

7 years ago

Aimmune's peanut allergy immunotherapy clears European PhIII with flying colors, paving way for first US, EU therapeutic approval

7 years ago

Humalog's list price may have gone up, but Lilly says it got paid less per sale in 2018 versus 2014

7 years ago

Price hikes, a strategic retreat and 1 big new approval has shaken up the rankings of the 20 most expensive drugs on the planet

7 years ago

FDA snubs Sanofi, Lexicon on their pitch for SGLT1/2 diabetes drug sotagliflozin, companies mum on what went wrong

7 years ago

As generic entry looms for its cash cow, Jazz wins FDA nod for follow-up sleep disorder drug

7 years ago

NASH drug in hand, Merck forges ahead with 2-year extension of NGM Bio collaboration deal

7 years ago

EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet

7 years ago

With eye on revenue stabilization, Gilead takes 4.9% hike on a basket of drugs

7 years ago

Pfizer lines up a potential $687M rare disease buyout to expand its stake in the hot gene therapy field

7 years ago

First page Previous page 276 277 278279280 281 282 Next page Last page